Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.375
+0.165 (+3.17%)
Streaming Delayed Price
Updated: 11:32 AM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
610,161
Open
5.210
Bid (Size)
5.370 (7)
Ask (Size)
5.380 (5)
Prev. Close
5.210
Today's Range
5.210 - 5.580
52wk Range
5.110 - 11.91
Shares Outstanding
81,632,619
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Today 8:00 EDT
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Performance
YTD
-46.14%
-46.14%
1 Month
-26.17%
-26.17%
3 Month
-25.45%
-25.45%
6 Month
-19.54%
-19.54%
1 Year
-35.24%
-35.24%
More News
Read More
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
March 07, 2024
Via
The Motley Fool
The Latest Analyst Ratings For Editas Medicine
February 29, 2024
Via
Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 2/28
February 28, 2024
Via
Investor Brand Network
Earnings Outlook For Editas Medicine
February 27, 2024
Via
Benzinga
1 Beaten-Down Stock With 55% Upside, According to Wall Street
March 04, 2024
Via
The Motley Fool
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
March 02, 2024
Via
The Motley Fool
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 28, 2024
Via
Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
February 28, 2024
Via
Investor's Business Daily
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
February 28, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
February 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
February 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
January 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
2 Under-the-Radar Stocks With Incredible Upside Potential
January 28, 2024
Via
The Motley Fool
Could Editas Medicine Become the Next CRISPR Therapeutics?
January 21, 2024
Via
The Motley Fool
7 Mighty Healthcare Stocks Changing the Game of Medicine
January 17, 2024
Via
InvestorPlace
Down 88%, Could Editas Medicine Be a Good Investment Now?
January 15, 2024
Via
The Motley Fool
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
Via
InvestorPlace
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
January 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
January 08, 2024
Via
The Motley Fool
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Via
MarketBeat
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
December 23, 2023
Via
The Motley Fool
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
December 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.